Loading...
 

Volume 35, Issue 1, March 2024



Sign in to download the Issue in PDF format.

Back to the list
Mediterr J Rheumatol 2022;33(3):311-5
Article Links
Prevalence of COVID-19 in Different Types of Collagen Vascular Diseases and its Relationship with Drugs Used in these Patients
Simin Almasi1, Elahe Mirzazade2, Dorsa Barzi3, Babak Eshrati4
Authors Information

1. Department of Rheumatology, Firouzgar Hospital, Iran University of Medical Science, Tehran, Iran

2. Firoozabadi Clinical Research Development Unit (FACRDU), Iran University of Medical Science (IUMS), Tehran, Iran

3. Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran

4. School of Medicine, Preventive Medicine and Public Health Research Centre, Social Injury Prevention Research Institute, Iran University of Medical Science

Keywords: COVID-19, collagen vascular, disease
References
  1. Arkadiusz S, Karolina O, Zaneta K, Bozena L. Cytokine Storms in the Course of COVID-19 and Haemophagocytic Lymphohistiocytosis in Pregnant and Postpartum Women. Biomolecules 2021;11(8):1202.
  2. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579:270–3.
  3. Favalli EG, Biggioggero M, Meroni PL. Methotrexate for the treatment of rheumatoid arthritis in the biologic era: still an “anchor” drug? Autoimmun Rev 2014;13:1102–8.
  4. Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG. Into the eye of the cytokine storm. Microbiol Mol Biology Rev Mmbr 2012;76:16–32.
  5. Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 2020 Jul; 79(7):859-66.
  6. Landewé RB, Machado PM, Kroon F, Bijlsma HW, Burmester GR, Carmona L and et al. EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Ann Rheum Dis. 2020 Jul; 79(7):851-858.
  7. D'Silva KM, Serling-Boyd N, Wallwork R, Hsu T, Fu X, Gravallese EM, et al. Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US ’hot spot’. Ann Rheum Dis 2020 Sep;79(9):1156–62.
  8. Favalli EG, Agape E, Caporali R. Incidence and Clinical Course of COVID-19 in Patients with Connective Tissue Diseases: A Descriptive Observational Analysis. J Rheumatol 2020 Aug 1;47(8):1296.
  9. Montero F, Martínez-Barrio J, Serrano-Benavente B, González T, Rivera J, Molina Collada J, et al. Coronavirus disease 2019 (COVID 19) in autoimmune and infammatory conditions: clinical characteristics of poor outcomes. Rheumatology International 2020;40:1593–8.
  10. Ferri C, Giuggioli D, Raimondo V, L'Andolina M, Tavoni A, Cecchetti R, et al . COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series. Clin Rheumatol 2020;39:3195–204.